You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
58 search results for: symposium
expert video
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
Dermatology
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
Under the Skin: Considerations for Atopic Dermatitis and Prurigo Nodularis in Clinical Practice
Dermatology
In this ADVENT symposium at the 2024 Diversity in Dermatology conference, experts Dr(s) Sarina Elmariah and Mona Shahriari engage in a dynamic discussion on diagnostic considerations for atopic dermatitis and prurigo nodularis and how clinical signs and itch in these diseases are impacted by type 2 inflammation.
Importance of Achieving Disease Control in Adults With Moderate-to-Severe AD
Dermatology
This video features Dr. Eric Simpson's presentation on the importance of achieving disease control in adults with moderate-to-severe AD. Dr. Simpson discusses how adult patients and HCPs talk about disease control and the tools available to help define it. He also explores the roles of IL-4 and IL-13 in the pathophysiology of AD, including how both cytokines promote inflammation and, in turn, contribute to the cumulative burden of the disease. The video concludes with a brief panel discussion.
Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.
Learn how the multidimensional, cumulative burdens of atopic dermatitis extend beyond the skin and across multiple organ systems, manifesting as atopic and non-atopic comorbidities. Even when an individual is performing well in spite of these burdens, they may still have significant life course impairment due to the cumulative impact of the disease.
A Tale of Two Itches: Bridging the Gap With Type 2 Inflammation in Prurigo Nodularis and Chronic Spontaneous Urticaria
Dermatology
Dr. Elmariah, Professor Metz, and Dr. Kim discuss the unique clinical presentations of PN and CSU and explore the shared and distinct pathophysiological underpinnings of itch and inflammation in both diseases, with a focus on the roles of type 2 cytokines at the neuroimmune axis In PN and CSU
Itch and Inflammation in Two Distinct Diseases: PN and CSU
Dermatology
Professor Metz discusses the unique clinical presentations of PN and CSU and explores the shared and distinct cellular underpinnings of itch and inflammation in both diseases
Connecting the Dots: Novel Insights on Type 2 Cytokines Mediating Neuroimmune Dysregulation in PN and CSU
Dermatology
Dr. Kim discusses the roles of type 2 cytokines at the neuroimmune axis In PN and CSU and conveys how neuroimmune interactions give rise to chronic itch and skin lesions in each disease
What We Know About Bullous Pemphigoid (BP): Challenges of the Various Clinical Manifestations, Diagnosis, and Burden for Patients and Caregivers
Dermatology
In this ADVENT symposium at the 2024 EADV meeting, Professor Joost Meijer highlights the heterogeneous nature of BP and the resultant burden for patients.
ATS 2024 | Type 2 Inflammation in the Pathophysiology of Asthma and COPD: What Is It and How Does It Impact Patients?
Pulmonology
Join leading experts for an educational symposium where they delve into the clinical consequences and real-world patient burden of type 2 inflammation in asthma and COPD.
Mechanisms of Disease: Autoimmunity and Role of Type 2 Inflammation in Bullous Pemphigoid (BP)
Dermatology
In this ADVENT symposium at the 2024 EADV meeting, Professor Enno Schmidt discusses the pathophysiology of BP, focusing on autoimmunity and the role of type 2 inflammation.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
All rights reserved. MAT-US-2305040 v3.0-P Exp. Date: 11/24/2025
All Rights Reserved.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.